Role of outcome trials in providing information on antihypertensive treatment: Importance and limitations

American Journal of Hypertension

Volumn 19, Issue 1, 2006, Pages 1-7

  Mancia, Giuseppe ^a,b,c,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIURETIC AGENT; LISINOPRIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CROSSOVER PROCEDURE; EDITORIAL; HUMAN; HYPERTENSION; MEDICAL INFORMATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; HUMANS; HYPERTENSION; PATIENT DROPOUTS; PATIENT SELECTION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 32344438818     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.10.009     Document Type: Editorial

References (44)

1. 2003 European Society of Hypertension/European Society of Cardiology Guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
2. A. Zanchetti Evidence-based medicine in hypertension. What type of evidence? J Hypertens 23 2005 1203 1209
3. Medical Research Council Medical Research Council Working Party MRC trial of treatment of mild hypertension principal results Br Med J 291 1985 97 104
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) J Am Med Assoc 288 2002 2981 2997
5. IPPPSH Collaborative Group Cardiovascular risk and risk factors in randomized trial of treatment based on the beta-blocker oxprenolol the International Prospective Primary Prevention Study in Hypertension (IPPPSH) J Hypertens 3 1985 379 392
6. L. Wilhelmsen, G. Berglund, D. Elmfeldt, T. Fitzsimons, H. Holzgreve, J. Hosie, P.E. Hornkvist, K. Pennert, J. Tuomilehto, H. Wedel Beta-blockers versus diuretics in hypertensive men main results from the HAPPHY trial J Hypertens 5 1987 561 572
7. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, K. Luomanmaki, B. Dahlof, U. de Faire, C. Morlin, B.E. Karlberg, P.O. Wester, J.E. Bjorck Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPP) randomised trial Lancet 353 1999 611 616
8. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, J. Lanke, U. de Faire, B. Dahlof, B.E. Karlberg Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
9. M.J. Brown, C.R. Palmer, A. Castaigne, P.W. de Leeuw, G. Mancia, T. Rosenthal, L.M. Ruilope Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372
10. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial Lancet 363 2004 2022 2031
11. L.H. Lindholm, H. Ibsen, B. Dahlof, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J. Edelman, S. Snapinn LIFE Study Group Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 1004 1010
12. L.M. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, G.L. Jennings, C.I. Johnston, J.J. McNeil, G.J. Macdonald, J.E. Marley, T.O. Morgan, M.J. West Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
13. C.J. Pepine, E.M. Handberg, R.M. Cooper-DeHoff, R.G. Marks, P. Kowey, F.H. Messerli, G. Mancia, J.L. Cangiano, D. Garcia-Barreto, M. Keltai, S. Erdine, H.A. Bristol, H.R. Kolb, G.L. Bakris, J.D. Cohen, W.W. Parmley INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST) a randomized controlled trial J Am Med Assoc 290 2003 2805 2816
14. H.R. Black, W.J. Elliott, G. Grandits, P. Grambsch, T. Lucente, W.B. White, J.D. Neaton, R.H. Grimm Jr, L. Hansson, Y. Lacourciere, J. Muller, P. Sleight, M.A. Weber, G. Williams, J. Wittes, A. Zanchetti, R.J. Anders CONVINCE Research Group Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial J Am Med Assoc 289 2003 2073 2082
15. V. Papademetriou, C. Farsang, D. Elmfeldt, A. Hofman, H. Lithell, B. Olofsson, I. Skoog, P. Trenkwalder, A. Zanchetti Study on Cognition and Prognosis in the Elderly study group Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension the Study on Cognition and Prognosis in the Elderly (SCOPE) J Am Coll Cardiol 44 2004 1175 1180
16. L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahlof, J. Lanke, B. Schersten, P.O. Wester, T. Hedner, U. de Faire Randomised trial of old and new antihypertensive drugs in elderly patients cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 354 1999 1751 1756
17. A. Zanchetti, G. Mancia Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach J Hypertens 14 1996 809 811
18. G.T. McInnes Clinical trials and tribulations Clin Exp Pharmacol Physiol 29 2002 951 955
19. SHEP Collaborative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension final results of the Systolic Hypertension in the Elderly Program (SHEP) J Am Med Assoc 265 1991 3255 3264
20. PROGRESS Collaborative Study Group Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
21. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
22. G. Mancia, G. Grassi Systolic and diastolic blood pressure control in antihypertensive drug trials J Hypertens 20 2002 1461 1464
23. G. Mancia, G. Grassi Rationale for the use of fixed combination in the treatment of hypertension Eur Heart J 1 Suppl L 1999 L14 L19
24. G. Mancia, R. Volpe, S. Boros, M. Ilardi, C. Giannattasio Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care J Hypertens 22 2004 51 57
25. G. Mancia, A.C. Pessina, B. Trimarco, G. Grassi SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice J Hypertens 22 2004 2387 2396
26. P. Primatesta, N.R. Poulter Hypertension management and control among English adults aged 65 years and older in 2000 and 2001 J Hypertens 22 2004 1093 1098
27. A.M. Sharma, H.U. Wittchen, W. Kirch, D. Pittrow, E. Ritz, B. Goke, H. Lehnert, D. Tschope, P. Krause, M. Hofler, H. Pfister, P. Bramlage, T. Unger HYDRA Study Group High prevalence and poor control of hypertension in primary care cross-sectional study J Hypertens 22 2004 479 486
28. M.R. Joffres, P. Hamet, D.R. MacLean, G.J. L'Italien, G. Fodor Distribution of blood pressure and hypertension in Canada and the United States Am J Hypertens 14 2001 1099 1105
29. R.H. Fagard, M. Van Den Enden, M. Leeman, X. Warling Survey and treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium J Hypertens 20 2002 1297 1302
30. J.R. Banegas, J. Segura, L.M. Ruilope, M. Luque, R. Garcia-Robles, C. Campo, F. Rodriguez-Artalejo, J. Tamargo CLUE Study Group Investigators Blood pressure control and physicians management of hypertension in hospital hypertension unit in Spain Hypertension 43 2004 1338 1344
31. W.C. Smith, A.J. Lee, I.K. Crombie, H. Tunstall-Pedoe Control of blood pressure in Scotland the rule of halves B Med J 300 1990 981 983
32. S. Julius Trials of antihypertensive treatment - new agenda for the millennium Am J Hypertens 13 2000 11S 17S
33. M. Wolz, J. Cutler, E.J. Roccella, F. Rohde, T. Thom, V. Burt Statement from the National High Blood Pressure Education Program prevalence of hypertension Am J Hypertens 13 2000 103 104
34. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure the JNC 7 report J Am Med Assoc 289 2003 2560 2571
35. D. Wood, G. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Piorala Prevention of coronary heart disease in clinical practice Eur Heart J 19 1998 1434 1503
36. G. De Backer, E. Ambrosioni, K. Borch-Johansen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebraihm, O. Faergeman, I. Graham, G. Mancia, V.M. Cats, K. Orth-Gomer, J. Perk, K. Pyorala, J.L. Rodicio, S. Sans, V. Sansoy, U. Sechtem, S. Silber, T. Thomsen, D. Wood European Guidelines on Cardiovascular Disease Prevention in Clinical Practice Eur J Cardiovasc Prev Rehabil 10 Suppl 1 2003 S1 S78
37. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, A.H. Barker, D. Arensberg, A. Baker, L. Friedman, H.L. Greene, J.T. Lee, K.T. Murray Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmias Suppression Trial N Engl J Med 324 1991 781 788
38. S. Fazio, M.F. Linton The role of fibrates in managing hyperlipidemia mechanisms of action and clinical efficacy Curr Atheroscler Rep 6 2004 148 157
39. E. Coodley Newer drug therapy for congestive heart failure Arch Intern Med 159 1999 1177 1183
40. L. Hansson, G. Mancia Evaluation of endpoints in hypertension Blood Press 6 Suppl 2 1997 1 123
41. J. Redon, L.M. Ruilope Microalbuminuria as an intermediate endpoint in essential hypertension evidence is coming J Hypertens 22 2004 1679 1681
42. R. Asmar, M. Safar, P. Queneau Pulse pressure an important tool in cardiovascular pharmacology and therapeutics Drugs 63 2003 927 932
43. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 31 1990 1561 1566
44. A. Simon, J. Gariepy, G. Chironi, J.-L. Megnien, J. Levenson Intima-media thickness a new tool for diagnosis and treatment of cardiovascular risk J Hypertens 20 2002 159 169